Modest efficacy of voriconazole against murine infections by Sporothrix schenckii and lack of efficacy against Sporothrix brasiliensis

Mycoses. 2014 Feb;57(2):121-4. doi: 10.1111/myc.12112. Epub 2013 Jul 23.

Abstract

The efficacy of voriconazole (VRC) was evaluated against two strains of each of the two most common species causing sporotrichosis, Sporothrix schenckii sensu stricto and Sporothrix brasiliensis, using a murine model of disseminated infection. Voriconazole was administered at doses of 20 or 40 mg kg(-1) per day by gavage. The drug showed some efficacy, especially at 40 mg kg(-1) per day, in prolonging the survival and reducing fungal load in spleen and liver in mice infected with S. schenckii, whereas in animals infected with S. brasiliensis the drug did not work.

Keywords: Voriconazole; animal model; sporotrichosis.

MeSH terms

  • Animals
  • Antifungal Agents / pharmacology
  • Antifungal Agents / therapeutic use*
  • Colony Count, Microbial
  • Disease Models, Animal
  • Liver / microbiology
  • Male
  • Mice
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use*
  • Spleen / microbiology
  • Sporothrix / drug effects*
  • Sporotrichosis / drug therapy*
  • Survival Analysis
  • Treatment Outcome
  • Triazoles / pharmacology
  • Triazoles / therapeutic use*
  • Voriconazole

Substances

  • Antifungal Agents
  • Pyrimidines
  • Triazoles
  • Voriconazole